Deep And Global Bioethics For A Livable Third Millennium

In three short years it will be Jan. 1, 2001, the first day of the 21st century and a new era. The United States will be expecting the inaugural message of a new president and the world will enter the Third Millennium. As the Second Millennium ends, we ought to think about what kind of a world we should and could realistically hope for. We certainly need a world with fewer than the often-predicted 12 billion people who may be present before the end of the 21st century. Unfortunately, in our mad

Written byVan Rensselaer Potter
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

In three short years it will be Jan. 1, 2001, the first day of the 21st century and a new era. The United States will be expecting the inaugural message of a new president and the world will enter the Third Millennium. As the Second Millennium ends, we ought to think about what kind of a world we should and could realistically hope for. We certainly need a world with fewer than the often-predicted 12 billion people who may be present before the end of the 21st century. Unfortunately, in our mad scramble to maintain the capitalistic civilization that attempts to accelerate excess consumption throughout the world, we give little thought to who sits at the table and who goes hungry. On the "Bridge to the 21st Century" we may preempt our chances of arriving at the 25th century or the year 3000. Will we exit from the third millennium ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies